Frontiers in Oncology (Apr 2022)
Prognostic Value of Heterogeneity Index Derived from Baseline 18F-FDG PET/CT in Mantle Cell Lymphoma
- Fei Liu,
- Fei Liu,
- Fei Liu,
- Fei Liu,
- Fei Liu,
- Bingxin Gu,
- Bingxin Gu,
- Bingxin Gu,
- Bingxin Gu,
- Bingxin Gu,
- Nan Li,
- Nan Li,
- Nan Li,
- Nan Li,
- Nan Li,
- Herong Pan,
- Herong Pan,
- Herong Pan,
- Herong Pan,
- Herong Pan,
- Wen Chen,
- Wen Chen,
- Wen Chen,
- Wen Chen,
- Wen Chen,
- Ying Qiao,
- Ying Qiao,
- Ying Qiao,
- Ying Qiao,
- Ying Qiao,
- Shaoli Song,
- Shaoli Song,
- Shaoli Song,
- Shaoli Song,
- Shaoli Song,
- Xiaosheng Liu,
- Xiaosheng Liu,
- Xiaosheng Liu,
- Xiaosheng Liu,
- Xiaosheng Liu
Affiliations
- Fei Liu
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China
- Fei Liu
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Fei Liu
- Center for Biomedical Imaging, Fudan University, Shanghai, China
- Fei Liu
- Shanghai Engineering Research Center of Molecular Imaging Probes , Shanghai, China
- Fei Liu
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai, China
- Bingxin Gu
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China
- Bingxin Gu
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Bingxin Gu
- Center for Biomedical Imaging, Fudan University, Shanghai, China
- Bingxin Gu
- Shanghai Engineering Research Center of Molecular Imaging Probes , Shanghai, China
- Bingxin Gu
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai, China
- Nan Li
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China
- Nan Li
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Nan Li
- Center for Biomedical Imaging, Fudan University, Shanghai, China
- Nan Li
- Shanghai Engineering Research Center of Molecular Imaging Probes , Shanghai, China
- Nan Li
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai, China
- Herong Pan
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China
- Herong Pan
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Herong Pan
- Center for Biomedical Imaging, Fudan University, Shanghai, China
- Herong Pan
- Shanghai Engineering Research Center of Molecular Imaging Probes , Shanghai, China
- Herong Pan
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai, China
- Wen Chen
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China
- Wen Chen
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Wen Chen
- Center for Biomedical Imaging, Fudan University, Shanghai, China
- Wen Chen
- Shanghai Engineering Research Center of Molecular Imaging Probes , Shanghai, China
- Wen Chen
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai, China
- Ying Qiao
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China
- Ying Qiao
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Ying Qiao
- Center for Biomedical Imaging, Fudan University, Shanghai, China
- Ying Qiao
- Shanghai Engineering Research Center of Molecular Imaging Probes , Shanghai, China
- Ying Qiao
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai, China
- Shaoli Song
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China
- Shaoli Song
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Shaoli Song
- Center for Biomedical Imaging, Fudan University, Shanghai, China
- Shaoli Song
- Shanghai Engineering Research Center of Molecular Imaging Probes , Shanghai, China
- Shaoli Song
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai, China
- Xiaosheng Liu
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China
- Xiaosheng Liu
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Xiaosheng Liu
- Center for Biomedical Imaging, Fudan University, Shanghai, China
- Xiaosheng Liu
- Shanghai Engineering Research Center of Molecular Imaging Probes , Shanghai, China
- Xiaosheng Liu
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai, China
- DOI
- https://doi.org/10.3389/fonc.2022.862473
- Journal volume & issue
-
Vol. 12
Abstract
ObjectivesMantle cell lymphoma (MCL) represents a group of highly heterogeneous tumors, leading to a poor prognosis. Early prognosis prediction may guide the choice of therapeutic regimen. Thus, the purpose of this study was to investigate the potential application value of heterogeneity index (HI) in predicting the prognosis of MCL.MethodsA total of 83 patients with histologically proven MCL who underwent baseline fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) were retrospectively enrolled. The clinicopathologic index and PET/CT metabolic parameters containing maximum and mean standard uptake value (SUVmax and SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and HI were evaluated. Receiver operating characteristic (ROC) curve analyses were performed to determine the optimal cutoff values of the parameters for progression-free survival (PFS) and overall survival (OS). Univariate and multivariate Cox regression were used to assess relationships between risk factors and recurrence. Kaplan–Meier plots were applied for survival analyses.ResultsIn univariate analyses, age [HR = 2.51, 95% CI = 1.20–5.24, p = 0.041 for body weight (BW)] and HI-BW (HR = 4.17, 95% CI = 1.00–17.38, p = 0.050) were significantly correlated with PFS. In multivariate analyses, age (HR = 2.61, 95% CI = 1.25–5.47, p = 0.011 for BW) and HI-BW (HR = 4.41, 95% CI = 1.06–18.41, p = 0.042) were independent predictors for PFS, but not for OS. B symptoms (HR = 5.00, 95% CI = 1.16–21.65, p = 0.031 for BW) were an independent prognostic factor for OS, but not for PFS. The other clinicopathologic index and PET/CT metabolic parameters were not related to outcome survival in MCL.ConclusionThe age and HI derived from baseline PET/CT parameters were significantly correlated with PFS in MCL patients.
Keywords
